Skip to main content
For laboratory research use only. Not for human or veterinary use.
Free UPS Ground on 3+ vials · same business day by 2 PM ET
Bench Grade Peptides

GLP-3 R (Retatrutide)

Triple-receptor incretin class agonist studied in metabolic-pathway research.

GLP-3 R is supplied by Bench Grade Peptides as a lyophilized powder in a sealed, lot-numbered vial, for laboratory research use only — not for human or veterinary use.

Its published Certificate of Analysis (lot 00011/0011, analyzed September 20, 2026) is from AV Analytics, a third-party laboratory, and reports 99.76% purity by HPLC; every published lot is listed on the product's COA page. Vials ship at ambient temperature in protective packaging from Florida (Bench Grade Peptides LLC is registered in Dover, Delaware), with storage notes on the lot's certificate.

GLP-3 R (Retatrutide) designates a synthetic analog in the triple receptor agonist class — the newest generation of incretin research compounds, engineered to engage the GIP, GLP-1, and glucagon receptors simultaneously. Adding glucagon-receptor activity to the dual-incretin profile brings energy-expenditure pathways into play alongside the insulin-secretion and satiety effects of the first two receptors.

The triple-agonist class is the current frontier of metabolic-pathway research, and laboratory demand has followed: receptor-pharmacology groups, adipose-biology labs, and signaling researchers all work with reference material from this family. The published record is young and moving quickly, which makes verified, consistent research material more important, not less.

GLP-3 R is one of the most ordered compounds in the Bench Grade catalog. Its lots are HPLC-verified, with Certificates of Analysis published in the COA library.

Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it has not been evaluated or approved by the FDA and is not for human or veterinary use, and nothing here is a protocol or a recommendation.

Published research

  • Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
    Jastreboff AM, et al. N Engl J Med. 2023.PubMed →

Further reading in the lab library

Researchers also ordered

Browse the catalog